PFS after alloHCT for R/R PTCL using conditioning with fractionated TBI (4  ×  2 Gy) and fludarabine by disease status at HCT. Single-center data from the University of Heidelberg; 44 consecutive patients transplanted 2010-2023; median follow-up 6.4 (range, 1.0-13.3) years. Blue curve, patients with sensitive disease; red curve, patients with refractory disease. CR, complete response; HR, hazard ratio; PD, progressive disease; PR, partial response; SD, stable disease.